Company Overview
Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration agreements with Cencora. Outlook Therapeutics, Inc. was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.
Recent Developments
- Trailing 12 Months Year-on-year growth — revenue -99.4%.
- 5-Year Trend Long-term compounding — revenue CAGR -15.1%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -15.06% |
| 1 Year: | -99.40% |
Stock Price Performance
| 1 Year: | -69.93% |
| 6 Months: | +42.97% |
| 3 Months: | -11.29% |
| 1 Month: | -37.21% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)36.23 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Revenue declined at -15.1% CAGR over 5 years.
- Trading 78.4% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | OTLK Outlook Therapeutics, Inc. PHARMA | 0.64 | -0.91 | $155.81M | 0.00% | - | - | -15.06% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2015 | Jun 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 1.51M | -91.79K | -1.21M | 127.44K |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 439.81K | 916.51K | 29.63K | 149.33K |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 1.07M | -1.01M | -1.24M | -21.89K |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 12.39M | 16.81M | 16.31M | 12.25M | 14.01M |
| Operating Income | -14.00M | -11.05M | -16.41M | -2.95M | -22.03M | -17.80M | -7.84M | -7.34M | -3.18M | -6.83M | -7.22M | -10.26M | -7.71M | -5.64M | -8.18M | -6.76M | -11.88M | -14.19M | -12.63M | -11.47M | -13.15M | -18.91M | -17.02M | -15.69M | -6.84M | -18.14M | -10.32M | -18.94M | -19.56M | - | -12.39M | -15.75M | -17.31M | -13.48M | -14.03M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -12.36M | -20.07M | -14.55M | -13.45M | -14.00M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 49.35K | 264.16K | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -46.35M | -20.15M | -14.85M | -23.06M | -4.45M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 2.80K | 0 | -1.55M | - | 0 |
| Net Income | -13.98M | -11.34M | -16.86M | -3.54M | -22.33M | -19.10M | -8.05M | -5.33M | -1.92M | -7.54M | -8.43M | -9.74M | -10.24M | -4.44M | -16.60M | -5.70M | -3.01M | -14.46M | -13.11M | -12.20M | -14.46M | -19.70M | -17.54M | -18.66M | -6.65M | -20.68M | -11.18M | -114.29M | 44.41M | - | -46.36M | -20.15M | -13.29M | -23.06M | -4.45M |
| Diluted EPS | - | - | - | -0.32 | -1.60 | - | -0.38 | -0.22 | - | -0.34 | -0.26 | - | - | - | - | - | -0.03 | -0.12 | -0.09 | -0.07 | -0.08 | -0.09 | -0.08 | -0.08 | -0.52 | -1.61 | -0.86 | -8.01 | -0.89 | 0.72 | -1.50 | -0.55 | - | -0.38 | -0.05 |
| R&D Expense | 10.15M | 9.68M | 12.73M | 4.14M | 12.02M | 13.23M | 4.12M | 4.16M | 402.40K | 5.16M | 5.80M | 6.07M | 5.94M | 4.34M | 5.85M | 4.38M | 8.49M | 11.95M | 8.53M | 8.55M | 9.87M | 12.22M | 11.25M | 9.86M | 544.95K | 11.10M | 4.53M | 13.51M | 11.20M | 9.66M | 4.41M | 7.13M | - | 3.63M | 4.50M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Sep 2015 | Sep 2016 | Sep 2017 | Sep 2018 | Sep 2019 | Sep 2020 | Sep 2021 | Sep 2022 | Sep 2023 | Sep 2024 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 5.22M | 2.98M | 3.81M | 3.09M | 8.15M | - | - | 0 | 0 | 0 | 1.41M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | 0 | 1.36M |
| Gross Profit | - | - | - | - | - | - | - | - | - | 0 | 57.20K |
| Operating Expenses | - | - | - | - | - | - | - | 63.07M | 53.13M | 71.70M | 67.12M |
| Operating Income | -46.56M | -51.35M | -35.88M | -29.64M | -36.30M | -36.84M | - | -63.07M | -53.13M | -71.70M | -67.06M |
| EBITDA | - | - | - | - | - | - | - | -64.36M | -56.40M | -72.09M | -63.58M |
| Interest Expense | - | - | - | - | - | - | - | 1.49M | 2.53M | 3.16M | 283.13K |
| Pretax Income | - | - | - | - | - | - | - | -66.05M | -58.98M | -75.36M | -63.98M |
| Tax Provision | - | - | - | - | - | - | - | 2.80K | 2.80K | 2.80K | -1.55M |
| Net Income | -47.39M | -53.30M | -38.85M | -30.09M | -34.52M | -35.24M | - | -66.05M | -58.98M | -75.37M | -62.42M |
| Diluted EPS | - | -3.67 | -1.80 | -1.22 | - | -0.67 | - | -6.20 | -4.80 | -4.06 | -1.79 |
| R&D Expense | 38.88M | 32.76M | 23.81M | 18.50M | 23.81M | 26.34M | 38.96M | 42.33M | 26.45M | 41.76M | 27.18M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Sep 2014 | Sep 2015 | Sep 2016 | Sep 2017 | Sep 2018 | Sep 2019 | Sep 2020 | Sep 2021 | Sep 2022 | Sep 2023 | Sep 2024 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 35.01M | 25.41M | 20.73M | 22.28M | 17.13M | 19.73M | - | 28.53M | 32.30M | 28.82M | 18.58M |
| Current Assets | - | - | - | - | - | - | - | - | 27.52M | 30.98M | 27.42M | 17.39M |
| Cash & Equivalents | 2.35M | 9.07M | 2.35M | 3.19M | 1.72M | 8.02M | 12.54M | - | 17.40M | 23.39M | 14.93M | 8.08M |
| Inventory | - | - | - | - | - | - | - | - | - | - | 0 | 3.34M |
| Receivables | - | - | - | - | - | - | - | - | - | - | 0 | 1.49M |
| Total Liabilities | - | 62.56M | 30.58M | 51.46M | 43.09M | 27.90M | 16.91M | - | 19.79M | 46.74M | 101.90M | 50.77M |
| Current Liabilities | - | 37.04M | 20.44M | 28.74M | 32.04M | 20.29M | 15.89M | - | 19.73M | 46.73M | 42.55M | 45.81M |
| Long Term Debt | - | 2.92M | 2.23M | 151.11K | 98.49K | 50.28K | - | 10.89M | - | - | - | - |
| Total Debt | - | - | - | - | - | - | - | - | 10.96M | 35.56M | 29.74M | 30.19M |
| Total Equity | - | -54.22M | -5.17M | -33.65M | -25.54M | -16.13M | 2.83M | - | 8.74M | -14.44M | -73.08M | -32.19M |
| Shares Outstanding | - | - | - | - | - | - | - | - | 11.37M | 13.01M | 23.91M | 53.89M |
Cash Flows (Annual)
Figures in USD.
| Metric | Sep 2015 | Sep 2016 | Sep 2017 | Sep 2018 | Sep 2019 | Sep 2020 | Sep 2021 | Sep 2022 | Sep 2023 | Sep 2024 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | -15.51M | -33.04M | -32.29M | -31.79M | - | -56.67M | -42.97M | -68.79M | -51.83M |
| Investing Cash Flow | - | - | -292.09K | -2.78M | -437.31K | -900.00K | 0 | - | - | - | - |
| Financing Cash Flow | - | - | 16.63M | 34.35M | 39.03M | 37.21M | - | 59.59M | 48.97M | 60.33M | 44.98M |
| Capital Expenditure | -8.80M | -1.10M | -292.09K | -2.78M | -437.31K | - | - | - | - | - | - |
| Free Cash Flow | - | - | -15.80M | -35.82M | -32.73M | - | - | -56.67M | -42.97M | -68.79M | -51.83M |
| Net Change in Cash | - | - | - | - | - | - | - | 2.92M | 6.00M | -8.46M | -6.84M |
Ratios (Annual)
Figures in %.
| Metric | Sep 2015 | Sep 2016 | Sep 2017 | Sep 2018 | Sep 2019 | Sep 2020 | Sep 2021 | Sep 2022 | Sep 2023 | Sep 2024 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | 4.0% |
| Operating Margin % | -892.1% | -1,723.3% | -941.4% | -960.1% | -445.6% | - | - | - | - | - | -4,744.3% |
| Net Margin % | -908.1% | -1,788.9% | -1,019.3% | -974.6% | -423.8% | - | - | - | - | - | -4,416.2% |
| ROE % | 87.4% | 1,030.4% | 115.4% | 117.8% | 214.0% | -1,246.8% | - | -756.0% | 408.5% | 103.1% | 193.9% |
| ROCE % | 2,290.4% | -1,033.3% | 448.3% | 303.8% | 1,150.5% | -958.5% | - | -716.9% | 368.1% | 522.2% | 246.3% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Vanguard Capital Management LLC | 1.80% | 4.38M | $2.86M |
| 2 | Perceptive Advisors Llc | 1.29% | 3.14M | $2.05M |
| 3 | Marshall Wace LLP | 0.82% | 1.99M | $1.30M |
| 4 | Blackrock Inc. | 0.69% | 1.67M | $1.09M |
| 5 | Jane Street Group, LLC | 0.59% | 1.43M | $930.13K |
| 6 | Geode Capital Management, LLC | 0.51% | 1.25M | $813.05K |
| 7 | Susquehanna International Group, LLP | 0.40% | 968.19K | $631.84K |
| 8 | HRT Financial LP | 0.32% | 784.90K | $512.23K |
| 9 | Vanguard Fiduciary Trust Co | 0.27% | 661.66K | $431.80K |
| 10 | Gilpin Wealth Management, LLC | 0.23% | 555.00K | $362.19K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for OTLK
OTLK Stock Surges On FDA Lytenava Application Resubmission After Successful Appeal - Stocktwits
<a href="https://news.google.com/rss/articles/CBMi3wFBVV95cUxOQlFzTExKNGFwbGdpNVhWSHZYTnZUaWVaSTFFRnRPQXMxTk0wUVNnSEtWbURCOGNraEJvakxlQlRkQWZDMTBtbVRjTWpib25pa2NoX25hODNXdTlUU0dtU1ZzWlRzY3lTazh5THI1MEhBVlNhVHJjT1hfMU9jcjlvU0lNWGN6N3lCZThVV2…
September US Stock Market Outlook: How to Position Your Portfolio During a Risky Stage - Morningstar
<a href="https://news.google.com/rss/articles/CBMiwgFBVV95cUxQbU4tR0FJTGY2LWY3Z3NUN2RNWUtOSVdWOUJxTEJUYnZVX1hNZGdHbVFqM1ZGVTV4TVdOYjhvSVZKdnA3RDRDUEUtQVkxQVNwMmoyZE5TZ2FFc0xiNGNEem53VTZoU1lHQzhqVF82bngxVTFYOTh2WjZIaG9IbmhHQl82TVFSM2V3UndhND…
Outlook Therapeutics (OTLK) Stock May Be No Bargain With Approval But Weak Balance Sheet - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMiogFBVV95cUxPdGVnczdlT0FuNFUzVXBFYy1QZDBQaXV5TndvYl9yNEE0OThLRkN3X18wbXVXcjdzejVjZVVvS0VIVE15R3E0c1lxRG55VHEyWDY3c1Z2VlVNZWl1YnJLZkZfNG5QU1BuVVA1U3dtdWFWcXBTMnlqVzRzQjVmYVgzWnNpeTZ5Y3JCTGxSYT…
CFO at Outlook Therapeutics (NASDAQ: OTLK) gets 500,000 hiring options - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiugFBVV95cUxOZXBpUjF1bWpvSzc0ODBUV2o3d3UwMEp3MXRGQTBRQzh4eG9md0dKdWxrcTV5YnNOUm5LZnJLSEllQ2xNUDQ3RGRVNXZrQ05rUDNOcVNhMnFpenFkVk0tb19DZHZWZXBwdWxYekQzV0FPcHpqVEpOVG9Vc0lrTV9ubFpQQ2Nwak1LWk9XeF…
Lululemon stock plunges 20% on disappointing earnings and outlook - CNBC
<a href="https://news.google.com/rss/articles/CBMid0FVX3lxTE5sa3JMSDdtMGZGVzdpcXBWb0dldnVKY2N1MlVmbnczS0xFM2hiUm9KOHZXUnNxc3Noa2ZQdy1McFdRenNFN3JEcFJ4LWtCUG5YZTFHY2xSNGVKdzk5M3hfQ0F6YWVHS0V6TWJmQWpqR1FJSFl4eHlJ?oc=5" target="_blank">Lululem…
Outlook Therapeutics to Report Third Quarter Fiscal 2026 Financial Results and Host Corporate Update Call on August 14, 2026 | OTLK Stock News - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMi8AFBVV95cUxQVWxSX3Jva3Y5MnJyUFo1dnV6WkVpSE9kcFR2N2hWemxoSElSbVhrOTNJWC1LWXIzVDRpdW9sd1pfUVhMUl85WVZ2N2MyQmRyUkNlWFVFNmZfOVNRQVU4N0lvbmhXSXFLa0ZuczdsQWNNU0lsX2JUd2dzOHRSX2hFNzBtcGpnanFaZjVzc2…
OTLK — Frequently Asked Questions
What is the current share price of Outlook Therapeutics, Inc. (OTLK)?
As of 2026-09-19 21:16 PDT, Outlook Therapeutics, Inc. (OTLK) trades at $0.64 on NasdaqCM. Its 52-week range is $0.20 to $2.97.
What is the market capitalisation of OTLK?
Outlook Therapeutics, Inc. (OTLK) has a market capitalisation of $155.81M on NasdaqCM.
What is the P/E ratio of OTLK?
OTLK trades at a trailing price-to-earnings (P/E) ratio of -0.91. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is -11.65.
Is OTLK a good stock to buy?
This page provides a data-driven analysis of Outlook Therapeutics, Inc. (OTLK), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.